EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Parvovirus B19 rebound outbreak 2024 and implications for blood‐ and plasma‐product safety

Maria R Farcet iD, Michael Karbiener iD, Claudia Aberham, Nicholas Powers, Daniel Aue, Thomas R Kreil iD

Transfusion · 2024-12 · 64 (12) · 2218-2221

DOI: 10.1111/trf.18032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transfusion, online erschienen am 03.10.2024. Verfasst von Maria R Farcet und 5 weiteren Autor:innen. Beteiligte Einrichtung: Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria. Hauptthemen laut MEDLINE: Parvovirus B19, Human, Blood Donors, Disease Outbreaks, Parvoviridae Infections. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Since the beginning of 2024, several European countries reported unusually high numbers of Human parvovirus B19 (B19V) infections. An increase in B19V incidence rate might have implications for blood products for direct transfusion, however, large data sets for analysis of this outbreak are missing. Study Design and Methods B19V nucleic acid testing (NAT) of plasma donations collected between June 2018 and May 2024 from mainly Central European countries ( n = 9.6 million) and the United States ( n = 70.7 million) was done to the individual donation level.

Results

In Central Europe, there was a marked increase in B19V incidence from November 2023 onwards, which peaked in April 2024 with a 33‐fold higher than average B19V incidence versus before the COVID‐19 pandemic. In the United States, a similar trend was seen, with a yet still 6‐fold lower increase than in Europe at the same time. The largest increase in B19V positivity was seen in the youngest plasma donor cohort.

Discussion

A B19V infection gap during the COVID‐19 pandemic is likely the basis for the rebound outbreak in 2023/2024, particularly in Europe. B19V NAT of millions of plasma donations provides for large scale numbers to solidify available epidemiology insight, and to support adequate risk assessments. Based on the situation it may be prudent to consider B19V NAT for blood components specifically directed towards transfusion to higher risk recipients, or alternatively, preselecting B19V seropositive individuals or advanced age donors at higher likelihood of seropositivity and thus lower risk of virus transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parvovirus B19, HumanBlood DonorsDisease OutbreaksParvoviridae InfectionsHumansEuropeFemaleAdultMaleMiddle AgedUnited StatesBlood SafetyCOVID-19PlasmaSARS-CoV-2IncidenceYoung AdultAgedBlood Component Transfusion

Stichwörter der Autor:innen

B19V epidemiologyparvovirus B19 outbreakre‐emergencerisk assessmenttransfusion transmission

Autor:innen und Institutionen

  • Global Pathogen Safety, Takeda Manufacturing Austria AG, Vienna, Austria.
  • Biolife, Takeda Manufacturing Austria AG, Vienna, Austria.
  • Biolife Plasma Services, Takeda, Social Circle, Georgia, USA.

ORCID-Profile: Maria R Farcet, Michael Karbiener, Thomas R Kreil

Zitieren

APA

Farcet, M. R., Karbiener, M., Aberham, C., Powers, N., Aue, D., & Kreil, T. R. (2024). Parvovirus B19 rebound outbreak 2024 and implications for blood‐ and plasma‐product safety. Transfusion, 64(12), 2218-2221. https://doi.org/10.1111/trf.18032

Vancouver

Farcet MR, Karbiener M, Aberham C, Powers N, Aue D, Kreil TR. Parvovirus B19 rebound outbreak 2024 and implications for blood‐ and plasma‐product safety. Transfusion. 2024;64(12):2218-2221. doi:10.1111/trf.18032

BibTeX
@article{Farcet2024,
  author = {Farcet, Maria R and Karbiener, Michael and Aberham, Claudia and Powers, Nicholas and Aue, Daniel and Kreil, Thomas R},
  title = {Parvovirus B19 rebound outbreak 2024 and implications for blood‐ and plasma‐product safety},
  journal = {Transfusion},
  year = {2024},
  volume = {64},
  number = {12},
  pages = {2218--2221},
  doi = {10.1111/trf.18032}
}
Kostenlos starten →